Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830063 · ClinicalTrials.gov registry record · Phase 3
Tanezumab In Osteoarthritis Of The Knee (2)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 832
- Enrollment target
NCT00830063 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 832 participants.
The verdict
NCT00830063, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 832 participants
- Enrollment target
Study Summary
The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.
Interventions
- OTHER placebo
- DRUG naproxen
- BIOLOGICAL tanezumab 10 mg
- BIOLOGICAL tanezumab 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 832 participants |
| Start Date | 2009-05-05 |
| Est. Completion | 2010-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00830063
The ClinicalTrials.gov registry entry for NCT00830063 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 832 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00830063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00830063 about?
NCT00830063 is a clinical study titled "Tanezumab In Osteoarthritis Of The Knee (2)". The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.
What is the current status of trial NCT00830063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 832 participants. The study started on 2009-05-05. Estimated completion is 2010-08-31.
What interventions are being tested in trial NCT00830063?
The interventions under investigation include: placebo (OTHER), naproxen (DRUG), tanezumab 10 mg (BIOLOGICAL), tanezumab 5 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00830063?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.